Tirofiban HCl | CAS#144494-65-5 | 150915-40-5

Tirofiban HCl hydrate
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318879

CAS#: 150915-40-5 (HCl hydrate)

Description: Tirofiban is an antiplatelet drug. It belongs to a class of antiplatelet named glycoprotein IIb/IIIa inhibitors. Tirofiban is the first drug candidate whose origins can be traced to a pharmacophore-based virtual screening lead. Tirofiban is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).

Chemical Structure

Tirofiban HCl hydrate

CAS# 150915-40-5 (HCl hydrate)

Instruction

Theoretical Analysis

MedKoo Cat#: 318879
Name: Tirofiban HCl hydrate
CAS#: 150915-40-5 (HCl hydrate)
Chemical Formula: C22H39ClN2O6S
Exact Mass: 440.23
Molecular Weight: 495.072
Elemental Analysis: C, 53.37; H, 7.94; Cl, 7.16; N, 5.66; O, 19.39; S, 6.48

Price and Availability

Size	Price	Availability
100mg	USD 650	2 weeks
250mg	USD 1250	2 weeks
500mg	USD 1950	2 weeks
1g	USD 2950	2 weeks
2g	USD 4250	2 weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Related CAS #: 150915-40-5 (HCl hydrate) 144494-65-5 (free base) 142373-60-2 (HCl)

Synonym: Aggrastat; L 700462; L-700,462; MK-383; MK 383; MK383; Tirofiban; Tirofiban hydrochloride monohydrate.

IUPAC/Chemical Name: N-(Butylsulfonyl)-4-(4-(4-piperidyl)butoxy)-L-phenylalanine monohydrochloride monohydrate

InChi Key: HWAAPJPFZPHHBC-FGJQBABTSA-N

InChi Code: InChI=1S/C22H36N2O5S.ClH.H2O/c1-2-3-16-30(27,28)24-21(22(25)26)17-19-7-9-20(10-8-19)29-15-5-4-6-18-11-13-23-14-12-18;;/h7-10,18,21,23-24H,2-6,11-17H2,1H3,(H,25,26);1H;1H2/t21-;;/m0../s1

SMILES Code: O=C(O)[C@H](CC1=CC=C(OCCCCC2CCNCC2)C=C1)NS(=O)(CCCC)=O.[H]Cl.[H]O[H]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info: Related CAS# CAS#150915-40-5 (Tirofiban HCl, monohydrate) CAS#144494-65-5 (Tirofiban free base)

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 495.07 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: King S, Short M, Harmon C. Glycoprotein IIb/IIIa inhibitors: The resurgence of tirofiban. Vascul Pharmacol. 2016 Mar;78:10-6. doi: 10.1016/j.vph.2015.07.008. Epub 2015 Jul 15. Review. PubMed PMID: 26187354.

2: Elcioglu OC, Ozkok A, Akpınar TS, Tufan F, Sezer M, Umman S, Besısık SK. Severe thrombocytopenia and alveolar hemorrhage represent two types of bleeding tendency during tirofiban treatment: case report and literature review. Int J Hematol. 2012 Sep;96(3):370-5. doi: 10.1007/s12185-012-1133-7. Epub 2012 Jul 6. Review. PubMed PMID: 22767141.

3: Guo J, Xu M, Xi Y. Tirofiban-induced diffuse alveolar hemorrhage: after primary angioplasty. Tex Heart Inst J. 2012;39(1):99-103. Review. PubMed PMID: 22412240; PubMed Central PMCID: PMC3298901.

4: Diaz JF, Cardenal R, Gomez-Manchero A, Sanchez-Gonzalez C. Safety and efficacy of tirofiban as adjunctive therapy for patients with ST-elevation myocardial infarction: a comparison versus placebo and abciximab. Cardiovasc Hematol Agents Med Chem. 2011 Jul 1;9(3):147-53. Review. PubMed PMID: 21718242.

5: Valgimigli M, Tebaldi M. Safety evaluation of tirofiban. Expert Opin Drug Saf. 2010 Sep;9(5):801-19. doi: 10.1517/14740338.2010.507189. Review. PubMed PMID: 20670206.

6: Juwana YB, Suryapranata H, Ottervanger JP, van 't Hof AW. Tirofiban for myocardial infarction. Expert Opin Pharmacother. 2010 Apr;11(5):861-6. doi: 10.1517/14656561003690005. Review. PubMed PMID: 20210689.

7: Valgimigli M, Biondi-Zoccai G, Tebaldi M, van't Hof AW, Campo G, Hamm C, ten Berg J, Bolognese L, Saia F, Danzi GB, Briguori C, Okmen E, King SB, Moliterno DJ, Topol EJ. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. Eur Heart J. 2010 Jan;31(1):35-49. doi: 10.1093/eurheartj/ehp376. Epub 2009 Sep 14. Review. PubMed PMID: 19755402.

8: van 't Hof AW, Valgimigli M. Defining the role of platelet glycoprotein receptor inhibitors in STEMI: focus on tirofiban. Drugs. 2009;69(1):85-100. doi: 10.2165/00003495-200969010-00006. Review. PubMed PMID: 19192938.

9: Winter JP, Juergens CP. The role of tirofiban in the management of coronary artery disease. Cardiovasc Hematol Disord Drug Targets. 2008 Jun;8(2):138-46. Review. PubMed PMID: 18537601.

10: Mukherjee D, Roffi M. Current strategies with high-dose tirofiban. Expert Opin Drug Metab Toxicol. 2007 Apr;3(2):275-80. Review. PubMed PMID: 17428156.

11: Bukow SC, Daffertshofer M, Hennerici MG. Tirofiban for the treatment of ischaemic stroke. Expert Opin Pharmacother. 2006 Jan;7(1):73-9. Review. PubMed PMID: 16370924.

12: Shanmugam G. Tirofiban and emergency coronary surgery. Eur J Cardiothorac Surg. 2005 Oct;28(4):546-50. Review. PubMed PMID: 16126403.

13: Patel S, Patel M, Din I, Reddy CV, Kassotis J. Profound thrombocytopenia associated with tirofiban: case report and review of literature. Angiology. 2005 May-Jun;56(3):351-5. Review. PubMed PMID: 15889207.

14: Menozzi A, Merlini PA, Ardissino D. Tirofiban in acute coronary syndromes. Expert Rev Cardiovasc Ther. 2005 Mar;3(2):193-206. Review. PubMed PMID: 15853593.

15: Mulot A, Moulin F, Fohlen-Walter A, Angioi M, Sghaier M, Carteaux JP, Lecompte T, de Maistre E. Practical approach to the diagnosis and management of thrombocytopenia associated with tirofiban treatment. Am J Hematol. 2004 Sep;77(1):67-71. Review. PubMed PMID: 15307109.

16: Kondo K, Umemura K. Clinical pharmacokinetics of tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist: comparison with the monoclonal antibody abciximab. Clin Pharmacokinet. 2002;41(3):187-95. Review. PubMed PMID: 11929319.

17: Doggrell SA. ReoPro rules: results from the 'Do Tirofiban and ReoPro Give Similar Efficacy Trial' (TARGET). Expert Opin Pharmacother. 2001 Sep;2(9):1507-9. Review. PubMed PMID: 11585028.

18: Bergquist PA, Manas D, Hunke WA, Reed RA. Stability and compatibility of tirofiban hydrochloride during simulated Y-site administration with other drugs. Am J Health Syst Pharm. 2001 Jul 1;58(13):1218-23. Review. PubMed PMID: 11449879.

19: Rasmussen S, Husted SE. [Tirofiban (Aggrastat). A non-peptide glycoprotein IIb/IIIa receptor inhibitor]. Ugeskr Laeger. 2001 Jan 22;163(4):461-5. Review. Danish. PubMed PMID: 11218789.

20: Galli M, Maggioni AP, Vassanelli C, Tavazzi L. [The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type]. Ital Heart J Suppl. 2000 Feb;1(2):202-11. Review. Italian. PubMed PMID: 10731377.

Your view history

Tirofiban HCl hydrate featured